| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands): | | | | | | | | | For the Quarter Ended March 31, 2026 | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | $ | 226,154 | | $ | 85,586 | | $ | 311,740 | Intersegment | | | | | | | | (325) | Consolidated net sales | | | | | | | $ | 311,415 | Segment operating income | | | | | | | | | Cost of sales | | 53,794 | | | 38,649 | | | | Selling, general and administrative | | 57,909 | | | 27,616 | | | | Research and development | | 14,452 | | | 9,002 | | | | Segment operating income | $ | 99,999 | | $ | 10,319 | | $ | 110,318 | Unallocated amounts | | | | | | | | | Amortization of intangibles | | | | | | | | (15,382) | Acquisition related expenses and other | | | | | | | | (897) | Certain litigation charges | | | | | | | | (822) | Stock based compensation, inclusive of employer taxes | | | | | | | | (10,968) | Restructuring and restructuring-related costs | | | | | | | | (2,952) | Corporate general, selling, and administrative expenses | | | | | | | | (3,802) | Consolidated operating income | | | | | | | $ | 75,495 |
| | | | | | | | | For the Quarter Ended March 31, 2025 | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | $ | 227,687 | | $ | 89,231 | | $ | 316,918 | Other revenue(1) | | | | | | | | — | Intersegment | | | | | | | | (737) | Consolidated net sales | | | | | | | $ | 316,181 | Segment operating income | | | | | | | | | Cost of sales | | 53,193 | | | 37,189 | | | | Selling, general and administrative | | 55,804 | | | 33,419 | | | | Research and development | | 14,780 | | | 10,200 | | | | Segment operating income | $ | 103,910 | | $ | 8,423 | | $ | 112,333 | Unallocated amounts | | | | | | | | | Amortization of intangibles | | | | | | | | (18,836) | Acquisition related expenses and other | | | | | | | | (5,159) | Certain litigation charges | | | | | | | | (38,927) | Stock based compensation, inclusive of employer taxes | | | | | | | | (11,629) | Restructuring and restructuring-related costs | | | | | | | | (716) | Recovery of assets held-for-sale | | | | | | | | 3,655 | Corporate general, selling, and administrative expenses | | | | | | | | (2,013) | Impact of business held-for-sale(1) | | | | | | | | — | Consolidated operating income | | | | | | | $ | 38,708 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023. | | | | | | | | | For the Nine Months Ended March 31, 2026 | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | $ | 643,426 | | $ | 246,224 | | $ | 889,650 | Other revenue | | | | | | | | 5,439 | Intersegment | | | | | | | | (1,242) | Consolidated net sales | | | | | | | $ | 893,847 | Segment operating income | | | | | | | | | Cost of sales | | 161,342 | | | 108,857 | | | | Selling, general and administrative | | 176,668 | | | 83,064 | | | | Research and development | | 43,089 | | | 26,674 | | | | Segment operating income | $ | 262,327 | | $ | 27,629 | | $ | 289,956 | Unallocated amounts | | | | | | | | | Amortization of intangibles | | | | | | | | (46,111) | Acquisition related expenses and other | | | | | | | | (6,341) | Certain litigation charges | | | | | | | | (5,370) | Stock based compensation, inclusive of employer taxes | | | | | | | | (37,262) | Restructuring and restructuring-related costs | | | | | | | | (14,201) | Recovery of assets held-for-sale | | | | | | | | 6,789 | Corporate general, selling, and administrative expenses | | | | | | | | (7,273) | Impact of business held-for-sale(1) | | | | | | | | (2,573) | Consolidated operating income | | | | | | | $ | 177,614 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since June 30, 2025. | | | | | | | | | For the Nine Months Ended March 31, 2025 | | | Protein Sciences | | | Diagnostics and Spatial Biology | | | Total | Net sales | $ | 643,774 | | $ | 256,558 | | $ | 900,332 | Other revenue(1) | | | | | | | | 4,152 | Intersegment | | | | | | | | (1,813) | Consolidated net sales | | | | | | | $ | 902,671 | Segment operating income | | | | | | | | | Cost of sales | | 157,618 | | | 108,417 | | | | Selling, general and administrative | | 170,420 | | | 102,002 | | | | Research and development | | 44,172 | | | 30,199 | | | | Segment operating income | $ | 271,564 | | $ | 15,940 | | $ | 287,504 | Unallocated amounts | | | | | | | | | Amortization of intangibles | | | | | | | | (57,136) | Acquisition related expenses and other | | | | | | | | (9,051) | Certain litigation charges | | | | | | | | (40,606) | Stock based compensation, inclusive of employer taxes | | | | | | | | (37,504) | Restructuring and restructuring-related costs | | | | | | | | (15,027) | Recovery of assets held-for-sale | | | | | | | | 3,655 | Corporate general, selling, and administrative expenses | | | | | | | | (5,241) | Impact of business held-for-sale(1) | | | | | | | | (479) | Consolidated operating income | | | | | | | $ | 126,115 |
(1) Includes the results of a business that has met the held-for-sale criteria since December 31, 2023.
|